<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01873768</url>
  </required_header>
  <id_info>
    <org_study_id>MOS-16735</org_study_id>
    <secondary_id>MOS1316735</secondary_id>
    <nct_id>NCT01873768</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement</brief_title>
  <official_title>A Randomized Controlled Trial of Tranexamic Acid and ε-Aminocaproic Acid to Reduce Blood Loss Following Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miller Orthopedic Specialists</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHI Health Mercy Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Creighton University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Miller Orthopedic Specialists</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid (TXA) and ε-aminocaproic acid (EACA) are two drugs shown to limit blood loss
      following major surgery, from cardiac to orthopedic procedures. Yet compared to tranexamic
      acid (TXA), research on the clinical impact of ε-aminocaproic acid (EACA) in total knee
      arthroplasty (TKA) is limited. The primary aim of this study is to determine whether TXA and
      EACA provide similar blood decreasing effects following TKA or whether one drug provides a
      superior effect over the other in reducing patients' blood loss.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transfusion rate</measure>
    <time_frame>1.5 to 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid (TXA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 50ml of saline will be infused over 30 minutes beginning at the time of wound closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ε-Aminocaproic Acid (EACA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 50ml saline will be infused over 30 minutes beginning at the time of wound closure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid (TXA)</intervention_name>
    <description>1g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 250cc of saline will be infused over 30 minutes beginning at the time of wound closure.</description>
    <arm_group_label>Tranexamic acid (TXA)</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ε-Aminocaproic Acid (EACA)</intervention_name>
    <description>7g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 250cc saline will be infused over 30 minutes beginning at the time of wound closure.</description>
    <arm_group_label>ε-Aminocaproic Acid (EACA)</arm_group_label>
    <other_name>Amicar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persons aged 18 - 90 years who are scheduled to undergo a unilateral total knee
             replacement surgery

        Exclusion Criteria:

          -  Non-English speaking individuals

          -  Individuals with a history of deep vein thrombosis or pulmonary embolism within one
             year

          -  Individuals with a history of coagulopathy

          -  Heart stent within one year

          -  Pre-operative autologous blood donation

          -  Unwilling or unable to take Coumadin for deep vein thrombosis (DVT) prophylaxis

          -  Received nonsteroidal anti-inflammatory drug (NSAID) or platelet antiaggregant
             treatment within five days prior to surgery

          -  Pre-operative creatinine greater than 1.5mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clifford K Boese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miller Orthopedic Specialists</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miller Orthopedic Specialists</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2013</study_first_submitted>
  <study_first_submitted_qc>June 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2013</study_first_posted>
  <last_update_submitted>March 18, 2016</last_update_submitted>
  <last_update_submitted_qc>March 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tranexamic acid</keyword>
  <keyword>6-Aminocaproic Acid</keyword>
  <keyword>Arthroplasty</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Joint Diseases</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Rheumatic Diseases</keyword>
  <keyword>Antifibrinolytic Agents</keyword>
  <keyword>Fibrin Modulating Agents</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Coagulants</keyword>
  <keyword>Therapeutic Uses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Aminocaproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

